Not a traditional drug phase: Manual expression of meibomian glands after thermal eyelid therapy for Dry Eye Syndrome (DES)
The goal of this study is to evaluate whether TearCare treatment stabilizes corneal measurements sufficiently to determine when cataract biometry can be considered reliable.
Official registry: https://clinicaltrials.gov/study/NCT07928986 · Cleveland Eye Clinic · enrollment listed as 36
What this phase means
This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.
They plan to enroll about 36 people at 2 sites. Taking part typically means using or being fitted with a device plus check-ins.
Official title (unrewritten)
A Multi Center, Peri-Cataract Evaluation of TearCare With Expression on Ocular Biometry and Surgical Measurements
Interventions: Manual expression of meibomian glands after thermal eyelid therapy
Primary outcome (registry wording): To determine the mean change and stability in IOL predicted power calculation using: Barrett Universal II, Kane Formula and Hill-RBF
Who it is for (from inclusion criteria)
- Ages 50 Years to 75 Years
- Diagnosis of MGD and DED
- TBUT \> 1 second and ≤ 7 seconds
- MGSS \<12 in both eyes
- ≥15 expressible meibomian glands
- Candidate for cataract surgery planning (ie. Phakic)
Who the registry excludes
- Cyclosporine, Xiidra, or serum tears within 30 days prior to Screening;
- Antihistamines (oral or topical) within 7 days prior to Screening;
- Oral tetracyclines or azithromycin within 30 days prior to Screening;
- Topical ophthalmic antibiotics, anti-glaucoma medications, steroids, nonsteroidal anti-inflammatory medications within 30 days prior to Screening
- Isotretinoin (e.g. Accutane) at any time
- Any of the following dry eye treatments:
- OAice-based dry eye treatment (e.g. IPL, TearCare, thermal pulsation \[LipiFlow\], iLuxetc.) within 12 months prior to Screening either as part of routine care or clinical investigation;
Public study contact (from the registry)
Erin Kus-Kreidler
ekus-kreidler@midwestvision.com
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
Sites listed on ClinicalTrials.gov
2 listed- The Eye Institute of West Florida — Largo, Florida (not_yet_recruiting)
- Cleveland Eye Clinic — Brecksville, Ohio (recruiting)
FAQ about this NCT record
Is NCT07928986 still recruiting?
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT07928986?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT07928986?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary